spacer
home > ebr > summer 2002 > why r&d matters
PUBLICATIONS
European Biopharmaceutical Review

Why R&D Matters

In his most recent Budget, the Chancellor announced the R&D tax credit for larger companies, complementing the R&D tax credit for small and medium-sized companies introduced in Budget 2000. Together the two credits will represent 500 million a year in additional Government support for business R&D investment in the UK. This level of commitment reflects the Government's determination to increase the level of R&D investment by UK industry. As Figure 1 shows, business R&D intensity in the UK does not fare well with comparable economies.Figure 1 shows the overall average business R&D intensity in the UK, but the picture varies from sector to sector. At 14.8 per cent of sales (1), R&D investment by the UK pharmaceutical industry is competitive by international standards - although recent years have seen a trend for UK-owned groups to undertake an increasing proportion of their R&D outside the UK, and we estimate a decline in the UK share of worldwide pharmaceutical R&D from 11 per cent to 9 per cent (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dawn Primarolo MP, Paymaster General for HM Treasury

Dawn Primarolo MP was appointed Paymaster General on 4th January 1999. She has overall responsibility for Inland Revenue and Customs and Excise duties and taxes, and for HM Treasury.
Member of Parliament for Bristol South since 1987, Dawn was educated at Thomas Bennet Comprehensive in Crawley, Bristol Poly and Bristol University. Before entering Parliament, she was member of Avon County Council from 1985 to 1987.
In Opposition, Ms Primarolo was Front Bench Spokesperson on health from 1992 to 1994, and Treasury affairs between 1994 and 1997. She was appointed Financial Secretary to the Treasury on 4th May 1997.

spacer
Dawn Primarolo MP
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement